🇺🇸

US SEC Filing Intelligence

· daily

Insider Trading Pulse — July 16, 2026

The July 16, 2026 insider trading pulse reveals a market dominated by routine equity compensation awards and tax-withholding sales, with limited outright buying or selling. A notable cluster of insider buying emerged in Sterling Real Estate Trust, where multiple officers and a 10% owner purchased shares on the open market at $25.50, signaling internal conviction in the company's value. Conversely, significant insider selling was concentrated in Essent Group Ltd., where the Chairman and CEO sold $5.13 million worth of shares under a 10b5-1 plan, and Sea Ltd., where the COO sold $1 million. The New Oriental Education & Technology Group saw multiple directors exercise options but sell a portion to cover taxes, a neutral signal. Overall, the day's activity suggests a cautious but not bearish sentiment, with real estate and credit funds attracting insider buying while financial and tech sectors saw profit-taking.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — July 16, 2026

The eight filings from Dow 30 constituents reveal a stark divergence between defensive growth and operational disruption. UnitedHealth Group (UNH) delivered a mixed quarter with strong earnings growth (adjusted EPS +23% YoY) and raised guidance, but faces significant membership attrition (-525K sequentially) and a decline in Optum scripts (-6.5% YoY), signaling headwinds in its core insurance and pharmacy businesses. Coca-Cola (KO) disclosed a ransomware attack at its high-growth fairlife subsidiary, temporarily halting US production—a material operational risk to a key growth driver. Meanwhile, routine insider transactions at Walmart (WMT) and Disney (DIS) (tax-withholding share disposals by executives) indicate no unusual conviction signals, but the sheer volume of filings (6 of 8) from these two companies highlights a period of standard equity compensation activity. The overarching theme is one of quality names facing idiosyncratic pressures: UNH's margin expansion is being offset by volume declines, KO faces a cybersecurity event in a prized asset, and WMT/DIS show no insider red flags. The portfolio-level pattern points to a 'show-me' environment where execution on growth drivers is critical.

6 high priority 2 medium 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 16, 2026

The July 16, 2026 digest reveals a severe escalation in corporate distress across small-cap US equities, with three of four filings detailing imminent or actual delisting events. The most critical development is Inotiv, Inc.'s confirmed Chapter 11 plan, which will cancel all existing common equity (35.2M shares) for zero recovery, marking a total loss for shareholders and a stark warning on the risks of distressed biotech/life sciences debt structures. Two additional companies, Cycurion and TG-17 (Our Bond, Inc.), face Nasdaq delisting due to persistent sub-$1.00 bid prices, with Cycurion's situation particularly acute as it has exhausted its compliance extension options after a prior reverse split. The sole positive signal comes from SRx Health Solutions, which resolved its NYSE American deficiency, demonstrating that compliance recovery is possible with operational improvement. A key period-over-period theme is the absence of insider buying across any distressed filer, while the aggregate trend shows a tightening of exchange listing standards, particularly for companies that have already executed reverse stock splits. The market implication is clear: the window for distressed micro-caps to regain compliance is narrowing, and equity holders in these situations face a high probability of total loss.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — July 16, 2026

The 42 filings from July 16, 2026, reveal a market sharply bifurcated between aggressive corporate restructuring and acute financial distress. A dominant theme is the wave of M&A and capital realignment, particularly in India, where companies like Aurum PropTech, HCLTech, and RSC International are executing high-value acquisitions and share swaps to consolidate market positions. Concurrently, a significant number of entities are facing existential threats: Inotiv, Winsome Yarns, and SpringBig Holdings are undergoing Chapter 11 or insolvency processes that will wipe out existing equity holders, while Mangalam Drugs and Cycurion face imminent default and delisting risks. The data shows a clear pattern of 'haves' using strong balance sheets to acquire growth, and 'have-nots' succumbing to debt and regulatory pressures. Insider activity is sparse but telling, with the Kobo Biotech insolvency failure and the Chart Industries/Baker Hughes merger completion representing the most material events. The forward-looking calendar is packed with shareholder meetings and regulatory deadlines, particularly in August 2026, which will be a critical month for many of these corporate actions.

42 high priority 42 total filings
· daily

US SEC Filings Daily Market Digest — July 16, 2026

Today's digest is dominated by transformative corporate actions: a major $14.8B cross-border bid from Uber for Delivery Hero, a prepackaged Chapter 11 wipeout for Inotiv, and a significant debt-for-equity swap at ASP Isotopes. The quarter's market sentiment from corporate results (GE Aerospace, UnitedHealth) is a clear 'mixed' picture: top-line expansion is accompanied by margin compression, elevated investment spending, and shrinking member rolls. The passive fund flows and insider activity paint a cautious picture, with two senior Sea Ltd executives selling under 10b5-1 plans, and the CEO of Essent Group liquidating ~$5M in stock. Capital allocation remains bifurcated: KB Financial completes a $600M buyback for cancellation, Dorian LPG pays a special $1/sh dividend from a vessel sale, while Inotiv equity goes to zero. The clearest forward-looking signal is Uber’s massive strategic pivot into food delivery with a H2 2027 target close, which, combined with GE’s upgraded full-year outlook, provides the strongest bullish catalysts in the pipeline.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 16, 2026

The sole filing in this digest is a Schedule 13G from JPMorgan Chase & Co. disclosing a passive 5.0% stake in Chipotle Mexican Grill Inc. as of June 30, 2026. This filing is a routine regulatory disclosure by a major institutional investor and does not indicate any active effort to influence management or strategy. The neutral sentiment and moderate materiality (5/10) suggest no immediate catalyst for the stock. However, the large block position (64.3M shares) held by a sophisticated asset manager could signal underlying confidence in Chipotle's long-term fundamentals, particularly given the company's strong brand and operational momentum in the fast-casual dining sector. No period-over-period comparisons, forward-looking guidance, insider trading, capital allocation actions, or transaction details were provided in this filing, limiting the depth of trend analysis. The key takeaway is that a major financial institution maintains a significant passive stake, which may provide a floor of institutional support but does not constitute a bullish or bearish signal on its own.

1 medium 1 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 16, 2026

The 10 filings reveal a mixed Q2 2026 for S&P 500 Healthcare. Revenue growth is uneven: Intuitive Surgical posted 19% YoY growth driven by 16% procedure volume expansion, while UnitedHealth saw only 0.4% top-line growth but a 54% surge in operating earnings. Abbott raised full-year adjusted EPS guidance but reported declines in Nutrition (-3.6% comparable) and Rapid Diagnostics (-8.0%). Key headwinds include UnitedHealth's 525,000 sequential membership drop (driven by Medicare Advantage and Medicaid exits) and Intuitive’s estimated 1% revenue tariff impact. Insider activity is bearish: Moderna’s President sold $3.6M in stock, and Gilead’s CCO and CFO each sold ~$390K. Capital allocation is mixed: Intuitive repurchased $0.38B in shares, while UnitedHealth completed an acquisition. The overarching theme is a divide between MedTech growth and managed care margin recovery versus core weakness in diagnostics and membership attrition.

7 high priority 3 medium 10 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 16, 2026

The 11 DEF 14A filings reveal a mixed picture for mid-cap and micro-cap companies, with several themes emerging around capital allocation, executive compensation, and shareholder governance. A standout is CSW Industrials, which reported record fiscal 2026 results with revenue surging 23.2% YoY to $1.1B, driven by aggressive M&A, though operating cash flow declined 11.1% YoY, signaling potential integration risks. Data Storage Corp completed a transformative $40M asset sale and repurchased 72% of its stock, leaving it debt-free but with a limited operating base. Several companies, including OSR Holdings and Actelis Networks, are seeking significant share increases (150M and 50M shares, respectively), which could dilute existing holders. Insider trading activity is notably absent across all filings, with no reported transactions, pledges, or holdings changes for named executives, which is a neutral signal but limits conviction insights. Forward-looking statements are sparse, with only CSW Industrials providing explicit guidance on challenged end markets due to tariffs. The most actionable opportunities lie in CSW Industrials' record performance and Data Storage Corp's cash-rich, debt-free balance sheet, while risks center on dilution proposals and the potential liquidation of Plum Acquisition Corp III if its extension vote fails.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 16, 2026

The IPO pipeline for July 16, 2026, is dominated by the S-1 filing of Phalanx Acquisition Corp I, a blank-check company targeting the real estate & construction sector. As a SPAC with no operating history, the filing provides no period-over-period comparisons, insider trading activity, or capital allocation data, limiting quantitative trend analysis. The offering includes multiple redemption scenarios (0% to 100%) and an over-allotment option, indicating flexibility in capital raising. The company's Cayman Islands incorporation and Puerto Rico address suggest a focus on non-US or tax-advantaged structures. The neutral sentiment and moderate materiality (5/10) reflect the early-stage nature of the filing, with no forward-looking guidance or financial metrics to evaluate. This filing represents a single data point in the IPO pipeline, with no sector-wide patterns or comparative insights available from other registrations.

1 high priority 1 total filings
· daily

USA Institutional Investor Activity — July 16, 2026

This digest covers a single 13F-HR filing from Ninety One UK Ltd for the period ended June 30, 2026, filed on July 16, 2026. As a quiet session with only one filing, the focus is on extracting maximum intelligence from the disclosed portfolio. The filing reveals a substantial, diversified equity portfolio with significant positions in mega-cap names like Microsoft, Johnson & Johnson, and Exxon Mobil, indicating a core-satellite or value-oriented strategy. While no quarter-over-quarter comparison data is available in the enriched fields to show position changes, the sheer size of disclosed holdings (e.g., 5.5M+ shares of Microsoft, 6.7M+ shares of J&J) provides a clear snapshot of the fund's current conviction. The neutral sentiment and low materiality score (4/10) suggest this is a routine quarterly disclosure, but the portfolio composition itself offers actionable insights into where a major global asset manager is allocating capital. Key themes include a tilt towards defensive, high-quality names and energy exposure, which may signal a cautious or inflation-hedging stance. The lack of insider trading, forward guidance, or capital allocation data in this filing type limits the depth of certain analyses, but the portfolio snapshot remains valuable for understanding institutional positioning.

1 medium 1 total filings
· daily

US SEC Trading Suspension Halt Orders — July 16, 2026

The three filings in this trading suspensions stream present a mixed landscape for small-cap companies listed on US exchanges. Cycurion, Inc. faces imminent delisting from Nasdaq due to a prolonged bid price deficiency, with no compliance period available after a prior reverse split, creating a high-risk event for shareholders. TG-17, Inc. (Our Bond, Inc.) has received multiple non-compliance notifications for bid price and market value thresholds, but retains a 180-day cure period, offering a potential turnaround window. In contrast, SRx Health Solutions, Inc. (SRX Global Inc.) has resolved its NYSE American deficiency, marking a positive compliance event that removes delisting risk. Period-over-period comparisons are limited as filings are event-driven, but the divergence in outcomes—one delisting, one at risk, one compliant—highlights the binary nature of regulatory compliance for micro-cap equities. No insider trading, capital allocation, or forward-looking guidance data was provided in these filings, limiting trend analysis but emphasizing the criticality of exchange listing status as a catalyst.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — July 16, 2026

This digest of 28 filings reveals a bifurcated market for executive and director changes, with most transitions being routine succession planning or governance adjustments, but a few high-conviction signals stand out. The most critical development is the leadership upheaval at BioRestorative Therapies, where the CEO and CFO resigned claiming a Change in Control, triggering a material uncertainty and potential $2.85M severance liability. Conversely, Snowflake’s board granted CEO Sridhar Ramaswamy a highly ambitious performance-based RSU award with escalating stock price targets up to $531, signaling strong alignment with long-term value creation. Harmony Biosciences delivered a standout operational performance with record Q2 revenue of $261M (up 30% YoY), but the simultaneous departure of its CFO creates a mixed signal. Sector themes include a notable cluster of biotech board appointments (Arcutis, enGene, Gyre Therapeutics) as companies prepare for key regulatory milestones, and a trend of founder/family-led CEO successions at John B. Sanfilippo & Son and Destiny Media Technologies. Overall, the data suggests a market where management teams are positioning for growth, but investors should scrutinize the few situations where insider departures coincide with governance disputes or financial uncertainty.

28 high priority 28 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 16, 2026

Inotiv, Inc. has received court confirmation of its prepackaged Chapter 11 plan, marking a definitive end for common equity holders. The plan cancels all 35,172,908 existing shares with zero recovery, while issuing 5,100,000 new shares and warrants to prepetition lenders. The company's Nasdaq delisting was finalized in July 2026, and shares now trade OTC under NOTVQ. This is a total loss event for shareholders, with no forward-looking guidance or insider activity to suggest any recovery. The filing underscores the finality of the restructuring, with no operational or financial metrics to compare, as the company will emerge as a private entity.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 16, 2026

The 28 filings reveal a mix of strategic board strengthening and leadership turmoil. Key themes include governance improvements (ProCap achieving Nasdaq compliance, BioRestorative addressing board gaps), biotech board expansions with experienced leaders (Arcutis, Gyre, enGene), and planned succession (Sanfilippo, PJT Partners, Union Bankshares). However, notable risks emerge from BioRestorative's disputed change-in-control and potential $2.85M severance, Harmony's CFO departure despite strong revenue growth (30% YoY), and several unexplained departures (Unity, Arhaus). Positive signals come from enGene's regulatory catalysts (pre-BLA meeting in 2H 2026) and Harmony's record revenue. The data underscores the importance of monitoring these transitions for execution risk and strategic shifts.

28 high priority 28 total filings
· daily

USA Insider Trading Pulse — July 16, 2026

Today's insider trading pulse reveals a bifurcated market: significant insider selling at Sea Ltd and Essent Group, contrasted by notable insider buying at Ares Dynamic Credit Allocation Fund and Sterling Real Estate Trust. The period-over-period data highlights a pattern of executive stock option awards at Atour Lifestyle and New Oriental Education, suggesting long-term incentive alignment but also creating potential overhang. The most critical development is the $5.13M sale by Essent Group's CEO under a 10b5-1 plan, which, while pre-arranged, signals a potential top. Conversely, the $4M purchase of preferred shares by a 10% owner at Ares Dynamic Credit Allocation Fund is a strong vote of confidence. Overall, the data suggests a cautious stance in high-growth tech (Sea Ltd) and financial services (Essent), while value/income plays (Ares, Sterling) are attracting insider capital.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 16, 2026

Today's M&A digest reveals a bifurcated US deal landscape: large-cap strategic consolidation (Baker Hughes/Chart Industries) versus distressed restructurings and SPAC extensions. The $4.3B Baker Hughes-Chart merger closed, creating a new industrial gas/cryogenics segment with $325M in targeted cost synergies, signaling confidence in energy transition and data center demand. Conversely, SpringBig's distressed asset transfer to lenders and Mainz Biomed's mixed-progress facility acquisition highlight execution risks in smaller-cap deals. Plum Acquisition Corp. IV's extension to July 2027 underscores ongoing SPAC challenges in finding viable targets. Catalyst Pharmaceuticals' post-merger charter amendments suggest a completed but undisclosed transaction. Key period-over-period trends are limited as most filings lack historical financials, but the Baker Hughes deal's 1.0-1.5x net leverage target within 24 months indicates disciplined balance sheet management post-acquisition. The overarching theme is a 'haves vs. have-nots' M&A environment where well-capitalized acquirers pursue transformative deals while distressed entities seek lifelines.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 16, 2026

Overnight SEC filings from July 15-16, 2026, reveal a mixed landscape of strong earnings, insider profit-taking, and significant corporate restructurings. UnitedHealth Group reported Q2 adjusted EPS of $6.38 (up 23.4% YoY) and raised full-year guidance, but membership declined by 525,000 sequentially, signaling a structural headwind. Insider selling was notable, with Clear Secure's CEO and director entity selling ~$10M combined and Essent Group's Chairman selling $5.13M, suggesting management may see current valuations as attractive for exits. Inotiv's Chapter 11 confirmation wiped out equity holders entirely, while XOMA Royalty's Nasdaq delisting and Senti Biosciences' potential 77.5% dilution highlight severe risks in small-cap biotech. On the positive side, capital returns accelerated: KB Financial completed a KRW 600B buyback (1.01% of shares) and plans cancellation, and Dorian LPG declared a $1.00 special dividend. Awareness Group's revenue surged 1,045% YoY, though it remains in negative equity. The overnight filings also revealed governance issues at IRIDEX (stealth proxy campaign) and notable acquisition activity by NextPlat and Stereotaxis. Overall, investors should focus on the dichotomy between strong earnings at large caps and severe dilution/bankruptcy risks in smaller names.

30 high priority 20 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 15, 2026

During the period of July 15, 2026, the FDA approved 4 biosimilar/fallback products, with zero NMEs, zero label expansions, and zero biosimilars (as defined by the stream's mix). All approvals are classified as 'Other' fallback entries, generating 4 neutral signals with no bullish or bearish catalysts. The dominant theme is generic/biosimilar market entries by small-cap sponsors including LAURUS, BELOTECA, APOTEX, and SQUARE PHARMS PLC, targeting established molecules (RILPIVIRINE HYDROCHLORIDE, ILOPROST, MAGNESIUM SULFATE, and an undisclosed drug). The highest-conviction signal is the lack of novel drug approvals, indicating a quiet period for pipeline-driven catalysts. Key risks include limited commercial differentiation and pricing pressure in mature therapeutic categories, with no IRA exposure flags due to the absence of branded drugs.

4 total filings
· daily

Big Pharma Approvals — July 15, 2026

This period's FDA digest covers a single label expansion approval for Eli Lilly's abemaciclib (Verzenio), classified as a 'fallback' type with a modest bullish signal. The approval mix is zero NMEs, zero biosimilars, and zero standard label expansions, making this a low-velocity week for new drug catalysts. The dominant signal is Eli Lilly's continued lifecycle management of its CDK4/6 inhibitor franchise, though the lack of commercial details (peak sales, pricing, exclusivity) limits conviction. Key watch items include potential competitive dynamics from Novartis' Kisqali and Pfizer's Ibrance in the adjuvant breast cancer setting, as well as IRA exposure risk for this small molecule. Investors should view this as a maintenance event rather than a transformative catalyst.

1 total filings
· daily

New Drug Approvals (Original) — July 15, 2026

The July 15, 2026 approval stream delivered four biosimilar/fallback approvals with zero NMEs, zero label expansions, and zero biosimilar designations explicitly flagged, resulting in a neutral signal across all events. The period lacked therapeutic area clustering, as approvals spanned RILPIVIRINE HYDROCHLORIDE (Laurus), ILOPROST (Beloteca), an undisclosed agent from Apotex, and MAGNESIUM SULFATE (Square Pharms PLC) — none with disclosed peak sales, exclusivity, or pricing data. The highest-conviction signal is the absence of any NME or breakthrough therapy approval, indicating a low-catalyst week for innovative biotech investors. Key risk: the lack of commercial detail on all four approvals limits actionable investment conclusions, and the undisclosed Apotex approval introduces opacity risk for competitive dynamics in its target market.

4 total filings